THE INFLAMMATORY STATUS AND LYMPH NODE METASTASES IN NON-SMALL CELL LUNG CANCER

Introduction. The development of inflammation is characterized by changes in blood hematology parameters and indices. Various inflammatory parameters are used to assess the inflammatory status (IS) during cancer treatment. Recent studies have revealed a relationship between tumor progression and the...

Full description

Saved in:
Bibliographic Details
Main Authors: D. S. Pismenny, O. E. Savelieva, M. V. Zavyalova, E. O. Rodionov, L. A. Tashireva, S. A. Tuzikov, O. V. Pankova, V. M. Perelmuter
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2020-07-01
Series:Сибирский онкологический журнал
Subjects:
Online Access:https://www.siboncoj.ru/jour/article/view/1488
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849408374986244096
author D. S. Pismenny
O. E. Savelieva
M. V. Zavyalova
E. O. Rodionov
L. A. Tashireva
S. A. Tuzikov
O. V. Pankova
V. M. Perelmuter
author_facet D. S. Pismenny
O. E. Savelieva
M. V. Zavyalova
E. O. Rodionov
L. A. Tashireva
S. A. Tuzikov
O. V. Pankova
V. M. Perelmuter
author_sort D. S. Pismenny
collection DOAJ
description Introduction. The development of inflammation is characterized by changes in blood hematology parameters and indices. Various inflammatory parameters are used to assess the inflammatory status (IS) during cancer treatment. Recent studies have revealed a relationship between tumor progression and the presence of chronic inflammation. Consequently, there have been many attempts to predict the risk of tumor recurrence and distant metastases, as well as patient’s survival assessing the various inflammatory markers. The relationship between IS parameters and lymph node metastasis remains poorly understood in non-small cell lung cancer (NSCLC).Material and Methods. The prospective study included 35 patients with NSCLC (T1–4N0–2M0). Seventeen patients received 2–3 cycles of neoadjuvant chemotherapy (NAC). A leukocyte formula was determined in the peripheral blood and inflammatory indices, such as neutrophils to lymphocytes ratio (NLR), platelets to lymphocytes ratio (PLR), lymphocytes to monocytes ratio (LMR) and systemic immuno-inflammatory index (SII) were calculated. In addition, the concentrations of fibrinogen, C-reactive protein (CRP) and cortisol were evaluated.Results. NAC alone did not significantly change the parameters of patients’ IS. Lymph node metastases were associated with changes in parameters indicating the enhanced IS. In the group of patients who did not receive NAC, lymph node metastasis was associated with fibrinogen blood levels (cut-off value 5.35 g/L), PLR index value (cut-off value 7.18) and cortisol blood concentration (cut-off value 414 nmol/mL). The confidence level was χ2 =10.118; р=0.018. In the group of patients who received NAC, lymph node metastasis was associated with the leukocyte count (cut-off value 7.1×109 /L), PLR index value (cut-off value is 7.18) and CRP blood concentration (cut-off value is 8.5 mg/L). The confidence level was χ2 =8.193; р=0.042.Conclusion. Risk of lymph node metastasis in NSCLC is associated with IS. Parameters of IS can be used to predict the risk of lymph node metastases.
format Article
id doaj-art-7268bbf69c584d3e8327b45dfb9bf9bc
institution Kabale University
issn 1814-4861
2312-3168
language Russian
publishDate 2020-07-01
publisher Russian Academy of Sciences, Tomsk National Research Medical Center
record_format Article
series Сибирский онкологический журнал
spelling doaj-art-7268bbf69c584d3e8327b45dfb9bf9bc2025-08-20T03:35:48ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682020-07-01193546310.21294/1814-4861-2020-19-3-54-63747THE INFLAMMATORY STATUS AND LYMPH NODE METASTASES IN NON-SMALL CELL LUNG CANCERD. S. Pismenny0O. E. Savelieva1M. V. Zavyalova2E. O. Rodionov3L. A. Tashireva4S. A. Tuzikov5O. V. Pankova6V. M. Perelmuter7Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical UniversityCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical UniversityCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical UniversityCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical UniversityCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesIntroduction. The development of inflammation is characterized by changes in blood hematology parameters and indices. Various inflammatory parameters are used to assess the inflammatory status (IS) during cancer treatment. Recent studies have revealed a relationship between tumor progression and the presence of chronic inflammation. Consequently, there have been many attempts to predict the risk of tumor recurrence and distant metastases, as well as patient’s survival assessing the various inflammatory markers. The relationship between IS parameters and lymph node metastasis remains poorly understood in non-small cell lung cancer (NSCLC).Material and Methods. The prospective study included 35 patients with NSCLC (T1–4N0–2M0). Seventeen patients received 2–3 cycles of neoadjuvant chemotherapy (NAC). A leukocyte formula was determined in the peripheral blood and inflammatory indices, such as neutrophils to lymphocytes ratio (NLR), platelets to lymphocytes ratio (PLR), lymphocytes to monocytes ratio (LMR) and systemic immuno-inflammatory index (SII) were calculated. In addition, the concentrations of fibrinogen, C-reactive protein (CRP) and cortisol were evaluated.Results. NAC alone did not significantly change the parameters of patients’ IS. Lymph node metastases were associated with changes in parameters indicating the enhanced IS. In the group of patients who did not receive NAC, lymph node metastasis was associated with fibrinogen blood levels (cut-off value 5.35 g/L), PLR index value (cut-off value 7.18) and cortisol blood concentration (cut-off value 414 nmol/mL). The confidence level was χ2 =10.118; р=0.018. In the group of patients who received NAC, lymph node metastasis was associated with the leukocyte count (cut-off value 7.1×109 /L), PLR index value (cut-off value is 7.18) and CRP blood concentration (cut-off value is 8.5 mg/L). The confidence level was χ2 =8.193; р=0.042.Conclusion. Risk of lymph node metastasis in NSCLC is associated with IS. Parameters of IS can be used to predict the risk of lymph node metastases.https://www.siboncoj.ru/jour/article/view/1488non-small cell lung cancerinflammatory statusneoadjuvant chemotherapylymph node metastasis
spellingShingle D. S. Pismenny
O. E. Savelieva
M. V. Zavyalova
E. O. Rodionov
L. A. Tashireva
S. A. Tuzikov
O. V. Pankova
V. M. Perelmuter
THE INFLAMMATORY STATUS AND LYMPH NODE METASTASES IN NON-SMALL CELL LUNG CANCER
Сибирский онкологический журнал
non-small cell lung cancer
inflammatory status
neoadjuvant chemotherapy
lymph node metastasis
title THE INFLAMMATORY STATUS AND LYMPH NODE METASTASES IN NON-SMALL CELL LUNG CANCER
title_full THE INFLAMMATORY STATUS AND LYMPH NODE METASTASES IN NON-SMALL CELL LUNG CANCER
title_fullStr THE INFLAMMATORY STATUS AND LYMPH NODE METASTASES IN NON-SMALL CELL LUNG CANCER
title_full_unstemmed THE INFLAMMATORY STATUS AND LYMPH NODE METASTASES IN NON-SMALL CELL LUNG CANCER
title_short THE INFLAMMATORY STATUS AND LYMPH NODE METASTASES IN NON-SMALL CELL LUNG CANCER
title_sort inflammatory status and lymph node metastases in non small cell lung cancer
topic non-small cell lung cancer
inflammatory status
neoadjuvant chemotherapy
lymph node metastasis
url https://www.siboncoj.ru/jour/article/view/1488
work_keys_str_mv AT dspismenny theinflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer
AT oesavelieva theinflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer
AT mvzavyalova theinflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer
AT eorodionov theinflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer
AT latashireva theinflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer
AT satuzikov theinflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer
AT ovpankova theinflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer
AT vmperelmuter theinflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer
AT dspismenny inflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer
AT oesavelieva inflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer
AT mvzavyalova inflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer
AT eorodionov inflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer
AT latashireva inflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer
AT satuzikov inflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer
AT ovpankova inflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer
AT vmperelmuter inflammatorystatusandlymphnodemetastasesinnonsmallcelllungcancer